GS
BHVN

George Soros’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

George Soros’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,272,535
Closed -$344M – 348
2022
Q3 		$344M Buy
2,272,535
+1,017,534
+81% +$151M 5.87% 2
2022
Q2 		$183M Buy
+1,255,001
New +$160M 3.26% 6

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

George Soros's BHVN Position: Q4 2022 in Review

George Soros sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 2,272,535 shares — an estimated $344M sold.

George Soros first reported a position in BHVN in Q2 2022 and held it in 2 quarters. The position peaked at $344M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • George Soros reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • George Soros sold 2,272,535 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $344M.
  • George Soros first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022 and held it in 2 quarters.
  • George Soros's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $344M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Soros Fund Management's 13F filing for Q4 2022, filed 13 Feb 2023.